ADVFN - Advanced Financial Network.
HOME» NYSE » V » VRX Stock Price » VRX Stock News

Valeant Pharma Share News

 Valeant Pharmaceuticals International Stock Price
VRX Stock Price
 Valeant Pharmaceuticals International Stock Chart
VRX Stock Chart
 Valeant Pharmaceuticals International Stock News
VRX Stock News
 Valeant Pharmaceuticals International Company Information
VRX Company Information
 Valeant Pharmaceuticals International Stock Trades
VRX Stock Trades

FTC Seeks Additional Info From Teva, Cephalon Regarding Merger

DOW JONES NEWSWIRES Teva Pharmaceutical Industries Ltd. (TEVA, TEVA.TV) and acquisition target Cephalon Inc. (CEPH) each received a request to provide additional information to the U.S. Federal Trade Commission related to a pending $6.8 billion deal between the firms. Israel-based Teva, which trumped a hostile offer from Valeant Pharmaceuticals International Inc. (VRX) in agreeing to buy Cephalon last month, said it had expected the request. The parties have been cooperating with the FTC staff since shortly after the bid was announced, according to Teva, which said it intends to win clearance "as promptly as possible." Teva on Monday said it continues to expect the deal to be completed in the third quarter, following clearance from U.S. and European regulators, as well as winning approval of Cephalon shareholders. Teva's American depositary shares were recently up 0.4% to $49.35 in after-hours trading. -By John Kell, Dow Jones Newswires; 212-416-2480; [email protected]

Stock News for Valeant Pharma (VRX)
DateTimeHeadline
02/23/201707:00:00Obagi Medical Products Announces Collaboration With Suzan Obagi...
02/23/201707:00:00Obagi Medical Products Announces Collaboration With Suzan Obagi...
02/21/201707:30:00Valeant Pharmaceuticals And EyeGate Enter Into Licensing Agreement...
02/21/201707:30:00Valeant Pharmaceuticals And EyeGate Enter Into Licensing Agreement...
02/16/201708:29:00AstraZeneca to Get $130 Million Payment as Psoriasis Drug Siliq...
02/16/201707:00:00Valeant Receives FDA Approval Of SILIQ™ (Brodalumab) For Moderate-To-Severe P...
02/16/201707:00:00Valeant Receives FDA Approval Of SILIQ™ (Brodalumab) For Moderate-To-Severe P...
02/14/201717:59:34Statement of Ownership (sc 13g)
02/13/201717:00:00Valeant Pharmaceuticals To Participate At Healthcare Conferences
02/13/201717:00:00Valeant Pharmaceuticals To Participate At Healthcare Conferences
02/13/201716:36:52Amended Statement of Beneficial Ownership (sc 13d/a)
02/13/201716:34:45Current Report Filing (8-k)
02/07/201712:25:01Amended Statement of Ownership (sc 13g/a)
01/30/201716:30:00Valeant To Hold Conference Call To Present Fourth Quarter And...
01/30/201716:30:00Valeant To Hold Conference Call To Present Fourth Quarter And...
01/17/201718:19:00Allergan Admits to Disclosure Violations During Valeant Bid
01/11/201703:03:00Valeant Sheds Assets to Pay Down Debt -- WSJ
01/11/201703:03:00L'Oréal Expands Its Strategy -- WSJ
01/10/201717:11:00Current Report Filing (8-k)
01/10/201716:13:52Current Report Filing (8-k)

Valeant Pharma and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US